DAT Scan in Parkinson’s Medical Diagnosis: An Expert Guide

Diagnosing Parkinson’s disease can be a complex journey, as there isn’t one definitive test to immediately confirm its presence. Instead, doctors rely on a comprehensive evaluation process to reach a diagnosis. This process, typically led by a neurologist — a specialist in nervous system disorders — involves a thorough review of your medical history, an in-depth analysis of your symptoms, and a detailed neurological and physical examination.

The path to a Parkinson’s diagnosis can sometimes take time. Healthcare professionals might schedule regular follow-up appointments with neurologists who specialize in movement disorders. These specialists carefully monitor your condition and symptoms over time, allowing for a more accurate assessment and diagnosis of Parkinson’s disease.

To aid in the diagnostic process and rule out other conditions that might mimic Parkinson’s, your healthcare team might recommend several tests and procedures:

• Physical and Neurological Exam: This cornerstone of diagnosis includes a detailed discussion of your medical history and a comprehensive neurological exam. This exam assesses various aspects of your neurological function, including cognitive abilities, mental sharpness, sensory functions, coordination, and reflexes.

• Blood and Laboratory Tests: While not directly diagnosing Parkinson’s, blood tests and other lab work are crucial to exclude other medical conditions that could be causing or contributing to your symptoms.

• Imaging Tests: Techniques like MRI, brain ultrasound, and PET scans are primarily used to rule out other neurological disorders. These imaging methods are generally not the primary tools for diagnosing Parkinson’s disease itself.

• Dopamine Transporter (DAT) Scan: A specialized type of SPECT scan, the DAT scan, can be a valuable tool in supporting a Parkinson’s disease diagnosis. It helps visualize the dopamine system in the brain and can differentiate between different types of tremors. However, it’s important to remember that the DAT scan is not the definitive diagnostic test. Your symptoms and the findings of the neurological exam remain the most critical factors in determining a diagnosis. Many individuals will not require a DAT scan as part of their diagnostic process.

• Genetic Testing: If there’s a family history of Parkinson’s disease, particularly early-onset Parkinson’s, genetic testing may be recommended to identify specific gene mutations associated with the condition.

• Medication Trial: In some cases, a doctor might prescribe a short course of Parkinson’s disease medications at a low dose. Observing your response to these medications can provide valuable diagnostic information. A significant improvement in symptoms with these drugs can strengthen the suspicion of Parkinson’s. It’s crucial to receive an adequate dose for a sufficient period to reliably assess the medication’s effect.

• Follow-up Appointments: Regular consultations with movement disorder specialists are often necessary to monitor symptom progression and confirm the diagnosis over time. Parkinson’s disease evolves, and ongoing assessment is key.

• Alpha-synuclein Test: This cutting-edge test, also known as the alpha-synuclein seed amplification assay, represents a significant advancement in Parkinson’s diagnosis. It has the potential to detect Parkinson’s even before the onset of noticeable symptoms. Alpha-synuclein is a protein that forms abnormal clumps called Lewy bodies, a hallmark of Parkinson’s disease. This test can detect these protein clumps in samples of skin or spinal fluid.

  Recent research, such as a 2023 study involving over 1,000 participants, has demonstrated the high accuracy of the alpha-synuclein seed amplification assay in spinal fluid. The test correctly identified Parkinson’s disease in nearly 88% of cases and showed high sensitivity in detecting individuals at risk of developing the disease. While these findings are promising and considered a potential breakthrough by some researchers, larger studies are still needed to validate these results and explore the test’s full potential. There is also ongoing research to develop a less invasive version of the test using blood samples instead of spinal fluid, which would make it more accessible and routine.

Parkinson’s Treatment Strategies

While there is currently no cure for Parkinson’s disease, effective treatments are available to manage symptoms and improve quality of life. Medications are often highly successful in controlling symptoms, and when medication effectiveness decreases, surgical options may be considered for some individuals. Beyond medical and surgical interventions, a comprehensive treatment plan often includes aerobic exercise, physical therapy focused on balance and flexibility, and speech therapy.

Medications for Symptom Management

Medications play a central role in Parkinson’s disease treatment, aiming to alleviate issues with movement, walking, and tremor. These drugs primarily work by increasing or mimicking the effects of dopamine in the brain, a neurotransmitter that is deficient in Parkinson’s disease. Direct dopamine administration is not possible as it cannot cross the blood-brain barrier.

Significant symptom improvement is often observed after starting medication. While the initial benefits might lessen over time, medications generally continue to provide good symptom control for many years.

Commonly prescribed medications include:

• Carbidopa-Levodopa (Rytary, Sinemet, others): Levodopa remains the most potent medication for Parkinson’s. It’s a naturally occurring chemical that converts to dopamine in the brain. Carbidopa is combined with levodopa to enhance levodopa’s delivery to the brain and reduce side effects like nausea.

  Potential side effects can include nausea and orthostatic hypotension (lightheadedness upon standing). Higher levodopa doses may induce involuntary movements (dyskinesia), requiring dose adjustments. The effectiveness of levodopa can fluctuate over time, sometimes leading to “wearing off” effects. For advanced Parkinson’s, carbidopa-levodopa is typically taken on an empty stomach, but it’s essential to follow your healthcare team’s specific instructions.

• Inhaled Levodopa (Inbrija): This medication is designed to manage “off” episodes, where oral medications suddenly stop working during the day.

• Carbidopa-Levodopa Infusion (Duopa): Delivered as a gel directly into the small intestine via a feeding tube (placed surgically), this infusion provides a more continuous levodopa supply. It is indicated for advanced Parkinson’s patients who respond to levodopa but need more stable drug levels. Potential risks associated with the feeding tube include dislodgement and infection at the insertion site. Duopa can help manage motor fluctuations and non-motor symptoms like anxiety and depression.

• Dopamine Agonists: These drugs mimic dopamine’s action in the brain but are generally less effective than levodopa for symptom control. However, they have a longer duration of action and can be used in conjunction with levodopa to improve its efficacy. Examples include:

  • Pramipexole (Mirapex ER)
  • Rotigotine (Neupro), available as a skin patch
  • Apomorphine (Apokyn), a short-acting injectable for rapid symptom relief

  Side effects can include lightheadedness, nausea, hallucinations, sleepiness, involuntary movements, and compulsive behaviors (e.g., hypersexuality, gambling, overeating). Report any unusual behaviors to your healthcare team.

• Monoamine Oxidase B (MAO B) Inhibitors: These medications block the enzyme monoamine oxidase B (MAO B), which breaks down dopamine in the brain, thereby prolonging dopamine’s effects. Examples include:

  • Selegiline (Zelapar)
  • Rasagiline (Azilect)
  • Safinamide (Xadago)

  When used with levodopa, MAO B inhibitors can help prevent levodopa from wearing off. Side effects may include headache, nausea, insomnia, confusion, and hallucinations (especially when combined with carbidopa-levodopa). MAO B inhibitors can interact with certain antidepressants and pain medications, so always consult your doctor before taking other drugs concurrently.

• Catechol O-methyltransferase (COMT) Inhibitors: These drugs enhance levodopa therapy by blocking COMT, another enzyme that breaks down dopamine. Examples include:

  • Entacapone (Comtan)
  • Opicapone (Ongentys)
  • Tolcapone (Tasmar), rarely used due to liver damage risk

  COMT inhibitors may increase the risk of involuntary movements and can cause diarrhea, nausea, or vomiting.

• Anticholinergics: Older medications, less commonly used now due to modest benefits and side effects. They can be helpful for managing severe tremor in some individuals. Examples include:

  • Benztropine
  • Trihexyphenidyl

  Side effects can include memory problems, urinary issues, confusion, blurred vision, dry mouth, and constipation.

• Amantadine (Gocovri): Used for short-term relief of mild, early Parkinson’s symptoms, and also with carbidopa-levodopa in advanced disease to control involuntary movements. Side effects may include skin discoloration (mottled skin), cognitive and memory problems, ankle swelling, hallucinations, and agitation.

• Adenosine Receptor Antagonists (A2A Receptor Antagonists): Istradefylline (Nourianz) is an example. These drugs help prevent dopamine “wearing off” and promote dopamine release. Research is ongoing to explore their potential in treating other Parkinson’s symptoms.

• Pimavanserin (Nuplazid): Specifically used to treat hallucinations and delusions that can occur in Parkinson’s disease.

Surgical Treatment: Deep Brain Stimulation (DBS)

For individuals whose symptoms are not adequately controlled by medication, deep brain stimulation (DBS) surgery may be an option.

Deep Brain Stimulation

DBS involves implanting electrodes deep within specific brain regions. These electrodes are connected to a device similar to a pacemaker, placed under the skin in the chest. The device delivers electrical pulses to the brain, modulating brain activity and reducing Parkinsonian symptoms. Post-surgery follow-up appointments are needed to fine-tune the stimulation settings for optimal symptom control. While DBS can significantly improve tremor and dyskinesia, and manage fluctuations in levodopa response, it does not halt Parkinson’s progression. Research continues to refine DBS techniques and improve outcomes.

Possible side effects of DBS include brain bleeding, tissue damage, infection, skin breakdown, muscle twitching, depression, and speech or vision problems.

Advanced and Minimally Invasive Treatments

MRI-guided focused ultrasound (MRgFUS) is a less invasive treatment for tremor management in certain Parkinson’s patients. Using MRI guidance, focused ultrasound waves are directed to brain areas responsible for tremor, creating heat to ablate these areas. Side effects can include walking and speech problems, and new involuntary movements.

Lifestyle Adjustments and Home Care

Lifestyle modifications can complement medical treatments and help manage Parkinson’s symptoms. It’s important to discuss any lifestyle changes with your healthcare team, as some remedies might interact with medications or exacerbate certain symptoms.

• Healthy Eating: While no specific diet cures Parkinson’s, a balanced diet is beneficial. High-fiber foods and ample fluid intake can help prevent constipation, a common issue. Omega-3 fatty acids and other nutrients in a balanced diet may also be helpful.

• Exercise: Regular exercise is crucial. It can improve muscle strength, balance, flexibility, and walking ability. Exercise can also have a positive impact on mood, reducing depression and anxiety. Consult a physical therapist to develop a tailored exercise program. Beneficial activities include walking, swimming, gardening, dancing, water aerobics, and stretching. To improve balance and gait, focus on heel-toe walking, looking straight ahead, and avoiding rushing.

• Fall Prevention: Falls are a significant concern. Strategies to prevent falls include: avoiding rushing, not multitasking, using handrails and nightlights, removing tripping hazards like throw rugs and cords, and learning safe turning and walking techniques (heel-first landing, upright posture). Assistive devices like walkers or canes may be recommended.

• Daily Living Activities Support: Occupational therapists can provide strategies for managing daily tasks like dressing and cooking. Speech therapists can assist with swallowing and speech difficulties.

Complementary and Alternative Therapies

Supportive therapies can help manage symptoms like pain, fatigue, and depression, and improve overall well-being when used alongside conventional medical treatments.

• Massage Therapy: Can reduce muscle tension and promote relaxation.

• Tai Chi: This ancient Chinese exercise uses slow, flowing movements to improve flexibility, balance, and muscle strength, potentially reducing fall risk.

• Yoga: Gentle stretching and poses can enhance flexibility and balance. Poses can be adapted to individual abilities.

• Alexander Technique: Focuses on posture, balance, and muscle use awareness to reduce tension and pain.

• Meditation: Promotes relaxation, stress reduction, pain management, and improved well-being through focused mental exercises.

• Relaxation Techniques: Practices like deep breathing and progressive muscle relaxation can lower blood pressure, heart rate, and muscle tension.

• Self-Hypnosis: Using self-suggestion to induce relaxation.

Coping and Support Systems

Living with a chronic condition like Parkinson’s disease can be emotionally challenging. Feelings of anger, depression, and discouragement are common. Parkinson’s can be particularly frustrating as everyday activities become more difficult. Depression is prevalent in Parkinson’s, but effective antidepressant medications are available. Seeking support is crucial.

While family and friends provide vital support, connecting with others who understand the Parkinson’s experience can be particularly beneficial. Support groups offer practical information, a sense of community, and emotional support. Maintaining usual activities and focusing on the present can also be helpful coping strategies. Mental health professionals experienced in chronic conditions can provide valuable guidance for both individuals with Parkinson’s and their families. Resources for finding support groups include healthcare teams, social workers, and organizations like the Parkinson’s Foundation and the American Parkinson Disease Association.

Preparing for Medical Appointments

When preparing for appointments, especially with a neurologist, it’s helpful to be organized.

• Symptom List: Document all symptoms, even seemingly unrelated ones.
• Personal Information: Note any major life changes or stressors.
• Medication List: Compile a list of all medications, vitamins, and supplements.
• Accompanying Person: If possible, have a family member or friend accompany you to help remember information.
• Questions List: Prepare questions in advance to make the most of your appointment time.

Essential questions to ask include:

• Likely cause of symptoms?
• Other possible causes?
• Necessary tests?
• Parkinson’s progression outlook?
• Need for long-term care?
• Available treatments and recommendations?
• Treatment side effects?
• Alternative treatment options if initial treatments are ineffective?
• Management of co-existing health conditions?
• Availability of educational materials and recommended websites?

Don’t hesitate to ask further questions that arise during the appointment. Your healthcare team is there to provide comprehensive information and support.

Your healthcare team will likely ask you questions as well, such as:

• When did symptoms begin?
• Are symptoms constant or intermittent?
• What improves symptoms?
• What worsens symptoms?

By Mayo Clinic Staff

Parkinson’s disease care at Mayo Clinic

Request an appointment

Symptoms & causes
Doctors & departments

Sept. 27, 2024

Print

Parkinson’s Disease Discussions

Colleen Young, Connect Director Living with Parkinson’s Disease – Meet others & come say hi 561 Replies Wed, Mar 05, 2025

chevron-right

Parkinson’s unresponsive episodes 80 Replies Wed, Feb 12, 2025

chevron-right

Is anyone using Rytary? 102 Replies Sat, Aug 24, 2024

chevron-right

See more discussions

1. Parkinson’s disease. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/parkinsons-disease#. Accessed April 3, 2024.
2. Kellerman RD. Parkinson’s disease. In: Conn’s Current Therapy 2024. Elsevier; 2024. https://www.clinicalkey.com. Accessed April 3, 2024.
3. Parkinson’s disease: Hope through research. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Parkinsons-Disease-Hope-Through-Research. Accessed April 3, 2024.
4. Loscalzo J, et al., eds. Parkinson’s disease. In: Harrison’s Principles of Internal Medicine. 21st ed. McGraw Hill; 2022. https://accessmedicine.mhmedical.com. Accessed April 4, 2024.
5. Stoker TB, et al. Parkinson’s disease: Pathogenesis and clinical aspects. htps://pubmed.ncbi.nlm.nih.gov/30702835/. Accessed April 4, 2024.
6. Ferri FF. Parkinson disease. In: Ferri’s Clinical Advisor 2022. Elsevier; 2022. https://www.clinicalkey.com. Accessed April 4, 2024.
7. Jankovic J, et al. Epidemiology, pathogenesis, and genetics of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 4, 2024.
8. Berg D, et al. Alpha-synuclein seed amplification and its uses in Parkinson’s disease. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00124-2.
9. Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using alpha-synuclein seed amplification: A cross-sectional study. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00109-6.
10. Post B, et al. Young onset Parkinson’s disease: A modern and tailored approach. Journal of Parkinson’s Disease. 2020; doi:10.3233/JPD-202135.
11. Ask Mayo Expert. Parkinson disease. Mayo Clinic; 2023.
12. Caproni S, et al. Diagnosis and differential diagnosis of Parkinson disease. Clinics in Geriatric Medicine. 2020; 10.1016/j.cger.2019.09.014.
13. Chou KL. Diagnosis and differential diagnosis of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 8, 2024.
14. Bower JH (expert opinion). Mayo Clinic. May 16, 2023.
15. Spindler MA, et al. Initial pharmacologic treatment of Parkinson disease. https://www.uptodate.com/contents/search. Accessed April 8, 2024.
16. Hauser RA, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson’s disease. Parkinsonism and Related Disorders. 2019; doi:10.1016/j.parkreldis.2019.03.026.
17. Mishima T, et al. Personalized medicine in Parkinson’s disease: New options for advanced treatments. Journal of Personalized Medicine. 2021; doi:10.3390/jpm11070650.
18. Jenner P, et al. Istradefylline — A first generation adenosine A2A antagonist for the treatment of Parkinson’s disease. Expert Review of Neurotherapeutics. 2021; doi:10.1080/14737175.2021.1880896.
19. Isaacson SH, et al. Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson’s disease psychosis. Journal of Parkinson’s Disease. 2020; doi:10.3233/JPD-202047.
20. Al-Shorafat DM, et al. β-blocker-induced tremor. Movement Disorders Clinical Practice. 2021; doi:10.1002/mdc3.13176.
21. Taghizadeh M, et al. The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurochemistry International. 2017; doi:10.1016/j.neuint.2017.03.014.
22. Parkinson’s disease: Fitness counts. Parkinson’s Foundation. http://www.parkinson.org/pd-library/books/fitness-counts. Accessed April 9, 2024.Green tea. Natural Medicines. https://naturalmedicines.therapeuticresearch.com. Accessed April 9, 2024.
23. Relaxation techniques for health. National Center for Complementary and Integrative Health. https://nccih.nih.gov/health/stress/relaxation.htm. Accessed April 9, 2024.
24. Haahr A, et al. ‘Striving for normality’ when coping with Parkinson’s disease in everyday life. A metasynthesis. International Journal of Nursing Studies. 2021; doi:10.1016/j.ijnurstu.2021.103923.
25. Mehanna R, et al. Age cutoff for early-onset Parkinson’s disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early-Onset Parkinson’s Disease. Movement Disorders Clinical Practice. 2022; doi:10.1002/mdc3.13523.
26. Nimmagadda R, Allscripts EPSi. Mayo Clinic. May 13, 2024.
27. Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: A cross-sectional study. The Lancet Neurology. 2023; doi:10.1016/S1474-4422(23)00109-6.
28. McKnight S, et al. Toxin-induced Parkinsonism. Neurologic Clinics. 2020; doi:10.1016/j.ncl.2020.08.003.